Worldwide Incidence and Prevalence of Neuromyelitis Optica
A Systematic Review
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 6, 2020
- Accepted in final form September 30, 2020
- First Published December 11, 2020.
Article Versions
- Previous version (December 11, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Viktoria Papp, MD, PhD,
- Melinda Magyari, MD, PhD,
- Orhan Aktas, MD,
- Thomas Berger, MD,
- Simon A. Broadley, MD, PhD,
- Philippe Cabre, MD,
- Anu Jacob, MD,
- Jun-ichi Kira, MD, PhD,
- Maria Isabel Leite, MD, DPhil,
- Romain Marignier, MD, PhD,
- Katsuichi Miyamoto, MD, PhD,
- Jacqueline Palace, MD,
- Albert Saiz, MD, PhD,
- Maria Sepulveda, MD,
- Olafur Sveinsson, MD, PhD and
- Zsolt Illes, MD, PhD
- Viktoria Papp, MD, PhD,
NONE
NONE
support for scientific meetings from Merck and Sanofi- Genzyme speaker honoraria from Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Odense University Hospital Research Fund: R72-A3846 the Danish MS Society: R561-A39086
NONE
NONE
NONE
NONE
NONE
NONE
- Melinda Magyari, MD, PhD,
(1)Biogen (2)Teva (3) Sanofi (3)Roche (4) Merck (5) Novartis (6) Alexion (7) Abbvie
NONE
(1)Biogen (2)Teva (3) Sanofi (4)Novartis (5) Almirall
NONE
NONE
NONE
NONE
(1) Roche (2) KORA: Det Nationale Institut for Kommuners og Regioners Analyse og Forskning (2) Department of Clinical Epidemiology à rhus University
NONE
NONE
NONE
(1)Biogen (2)Teva (3) Sanofi (3)Roche (4) Merck (5) Novartis
NONE
NONE
The Danish Multiple Sclerosis Society Fonden for Neurologisk Forskning Direktør Ejnar Jonasson, kaldet Johnsen og HustruÂs Mindelegat Lundbeck Fonden
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD,
(1) Medimmune Scientific Advisory Board
NONE
(1) Bayer, travel and speaker honoraria (2) Novartis, travel and speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, travel and speaker honoraria (6) Sanofi-Genzyme, travel and speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
(1) Novartis (2) Celgene
NONE
NONE
NONE
(1) Biogen (2) Sanofi-Genzyme (3) Novartis
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Berger, MD,
(1) Biogen (2) Celgene (3) MedDay (4) Merck (5) Novartis (6) Roche (7) Sanofi Aventis/Genzyme
NONE
(1) Biogen (2) Celgene (3) Merck (4) Novartis (5) Roche (6) Sanofi Aventis/Genzyme (7) Almirall (8) Bionorica (9) Biologix (10) UCB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Simon A. Broadley, MD, PhD,
(1) Alexion, (2) Biogen Idec, (3) Merck, (4) Roche, (5) NervGen, (6) Novartis, (7) Roche, (8) Sanofi
NONE
(1) Roche, speakers honoraria, (2) Merck, travel sponsorship, (3) Biogen Idec, travel sponsorship, (4) Sanofi, speakers honoraria, (5) Roche, speakers honoraria, (6) Sanofi-Genzyme, travel sponsorship, (7) Roche, travel sponsorship
(1) Multiple Sclerosis Journal - Experimental, Translational and Clinical, Editor, 0.4 years
NONE
NONE
NONE
NONE
NONE
(1) Multiple Sclerosis Research Australia, I chair the Research Management Committee (granting body) (2) Australian and New Zealand Assocaition of Neurologists, I chair the MS Neurology Group
NONE
NONE
(1) National Health and Medical Research Council, 1127819, CI, 2017-21, (2) Australian Research Council, DP180100089, CI, 2018-20, (3) National Health and Medical Research Council (Medical Research Future Fund), 1152317, CI, 2018-20
NONE
(1) Gold Coast Hospital Foundation, RGS2017-LG0003, CI, 2018- 19
NONE
NONE
NONE
NONE
NONE
NONE
- Philippe Cabre, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anu Jacob, MD,
Shire Pharmaceuticals SINAPPS trial ( Addenbrookes hospital UK )
NONE
Honoraria for speaking on NMO from Biogen Idec and Shire Terumo BCT, Veilo Bio Pharamecuticals
NONE
NONE
NONE
NONE
Commercial Entity Shire Pharmaceuticals
Honoraria for speaking on NMO from Biogen Idec, Shire,Terumo BCT, Veilo Bio
NONE
NONE
NONE
UK NHS -NMO service
UNIVERSITY OF LIVERPOOL
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jun-ichi Kira, MD, PhD,
NONE
NONE
JK received speaking fees and/or honoraria from (1) Novartis Pharma, (2) Mitsubishi Tanabe Pharma, (3) Boehringer Ingelheim, (4) Teijin Pharma, (5) the Takeda Pharmaceutical Company, (6) Otsuka Pharmaceutical, (7) Astellas Pharma, (8) Pfizer Japan, and (9) Eisai.
(1) Multiple Sclerosis Journal, Editorial Board Member, 2006-, (2) BMC Medicine, Editorial Board Member, 2010-, (3) Journal of the Neurological Sciences, Editorial Board Member, 2010-, (4) Multiple Sclerosis and Related Disorders, Editorial Board Member, Section Editor, 2011-, (5) PLOS ONE, Editorial Board Member, 2011-, (6) Frontiers in Immunology, Associate Editor, 2017-
NONE
NONE
NONE
(1) Biogen Japan (consultancy, since 2009)
NONE
NONE
NONE
(1) Novartis Pharma, (2) Boehringer Ingelheim, (3) Teijin Pharma, (4) Takeda Pharmaceutical Company, (5) Otsuka Pharmaceutical, (6) Astellas Pharma, (7) Pfizer Japan, (8) Eisai, (9) Dainippon-Sumitomo Pharmaceutical, (10) Tanabe- Mitsubishi Pharmaceutical, (11) Japan Blood Products Organization, (12) Bayer
(1) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 25117012, Principal Investigator, 2013-2018, (2) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 25117001, Co- investigator, 2013-2018, (3) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 15K21729, Co-investigator, 2015-2018, (4) Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI), 15K15341, Principal Investigator, 2015-2017, (5) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 15K09343, Co- investigator, 2015-2018, (6) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 16K10727, Co- investigator, 2016-2019, (7) Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI), 16H02657, Principal Investigator, 2016-2019, (8) Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI), 17K19663, Principal Investigator, 2017-2019, (9) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 18K07529, Co- investigator, 2018-2021, (10) Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI), 19H01045, Principal Investigator, 2019-2022, (11) Practical Research Project for Rare/Intractable Diseases
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Isabel Leite, MD, DPhil,
None
NONE
Dr. Maria Isabel Leite is supported by NHS National Specialised Commissioning Group for Neuromyelitis Optica, UK, and by NIHR Oxford Biomedical Research Centre, and has received travel grant and speaking honoraria from Biogen Idec and travel grant from Novartis.
Neuromuscular Disorders, editorial board member, from January 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Marignier, MD, PhD,
Dr Marignier is serving on a scientific advisory board of Viela Bio
NONE
Romain Marignier has received lecturing fees and travel grants from Biogen, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katsuichi Miyamoto, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline Palace, MD,
All commercial (advisory boards last 2 years) 1) Merck Serono 2) Roche 3) ARGENX 4) Chugai 5) Novartis 6) UCB 7) Alexion
NONE
All commercial (speakers/meetings honorarium last two years) 1) Merck Serono 2) Novartis 3) Viela Bio 4) UCB 5) Roche 6) Alexion
NONE
ISIS Innovation Ltd. To protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis. Reference EP2812690B1
NONE
NONE
All commercial (advisory boards last two years) 1) Merck Serono 2) Roche 3) Argenx 4) Chugai 5) Novartis 6) UCB 7) Alexion Commercial (consultancy) 1) Merck Serono 2) UCB 3)RA Pharma 4) Mitsubushi 5) Roche 6) Amplo 7) Alexion
Please see 3 (speaker/meetings)
NONE
NONE
All commercial (support for research) 1) Merck Serono 2) MedImmune
NONE
NONE
Grant for research: 1) Multiple Sclerosis Society 2) Guthry Jackson 3) NIHR 4) Medical Research Council 5) MyWare Clinical Training Fellowship 6) SPARKS Great Ormond Street 7)AMPLO
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD, PhD,
NONE
NONE
compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd, Novartis, Alexion,and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Sepulveda, MD,
NONE
NONE
I have received speaking honoraria from: 1)Sanofi, type of payment: 500 euros for a talk 2) Novartis, 300 euros for a talk 2)Biogen, 500 euros for a talk
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have received a grant from the Departament de Salut de la Generalitat de Catalunya, number SLT002/16/00354, as neurologist, from 2017 to 2019.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olafur Sveinsson, MD, PhD and
1) Advisory board for Biogen Idec on the medication Plegridy for MS.
NONE
1) Travel funding from Biogen Idec 2) Travel funding from UCB 3) Travel funding from Sandoz
NONE
NONE
NONE
NONE
1) Consultant for Biogen Idec on Plegridy and Zinbryta.
NONE
Received consulting fees from Biogen, other from Biogen, other from UCB and Sandoz, outside the submitted work.
NONE
NONE
1) The study was supported by Stockholm County Council, GlaxoSmithKline and Citizens United for Research in Epilepsy (CURE).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Zsolt Illes, MD, PhD
(1) Biogen (2) Novartis (3) Sanofi-Aventis-Genzyme (4) Teva Pharmaceuticals (5) Roche
NONE
(1) Biogen Idec (2) Novartis (3) Sanofi-Aventis-Genzyme (4) Teva Pharmaceuticals (5) Bayer Healthcare (6) Merck Serono (7) Roche
(1) Clinical and Experimental Neuroimmunology (2) Frontiers in Neurology (3) Frontiers in Immunology
Lambertsen K, Clausen B, Nielsen HH, Finsen B, Illes Z. 2015. Fumaric acid derivates for Medical use. No. PCT/DK2015/050344. The use of fumaric acid derivates in acute ischemic stroke.
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Merck (2) Sanofi-Genzyme
Region of Southern Denmark, primary investigator, 2014 Odense University Hospital, primary investigator, 2016
NONE
(1) Scleroseforeningen (2) Lundbeckfonden (3) Direktor Ejnar Jonasson, kaldet Johnsen, og Hustru's Mindelegat (4) Jascha Fonden
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (V.P., Z.I.), Odense University Hospital; Danish Multiple Sclerosis Center (M.M.), Copenhagen University Hospital, Rigshospitalet, Denmark; Department of Neurology (O.A.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; Menzies Health Institute Queensland (S.A.B.), Griffith University, Gold Coast; Department of Neurology (S.A.B.), Gold Coast University Hospital, Australia; Department of Neurology (P.C.), Fort-de-France University Hospital Center, Pierre Zobda Quitman Hospital, Fort-de-France, Martinique, France; Department of Neurology (A.J.), The Walton Centre, Liverpool, UK; Cleveland Clinic (A.J.), Abu Dhabi, United Arab Emirates; Departments of Neurology (J.K., J.P.), Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Nuffield Department of Clinical Neurosciences (M.I.L., J.P.), John Radcliffe Hospital, University of Oxford, UK; Service de Neurologie (R.M.), Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, et Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Department of Neurology (K.M.), Kindai University Graduate School of Medicine, Osaka, Japan; Center of Neuroimmunology (A.S., M.S.), Service of Neurology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain; Department of Neurology (O.S.), Karolinska University Hospital and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Institute of Clinical Research (Z.I.), University of Southern Denmark, Odense, Denmark; and Institute of Molecular Medicine (Z.I.), University of Southern Denmark, Odense.
- Correspondence
Dr. Illes zsolt.illes{at}rsyd.dk
Article usage
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.